Revium Rx.

8-K · ea0292932-8k_revium.htm iXBRL

0001839140

 2026-05-27
 2026-05-27

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

  

 Form 8-K

  

 CURRENT REPORT

 Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

  

 Date of Report (Date of earliest event reported):
 May 27, 2026

  

 REVIUM Rx.

 (Exact Name of Registrant as Specified in its Charter)

  

 Nevada
  
 333-284934
  
 84-4516676

 (State or other jurisdiction

of incorporation)
  
 (Commission File Number)
  
 (I.R.S. Employer

Identification No.)

  

 Azrieli Business Center 89, Medinat Hayehudim Street

 Herzliya , Israel
  
 10017

 (Address of Principal Executive Offices)
  
 (Zip Code)

  

 Registrant’s telephone number, including
area code: 1 800 519-1687

  

 n/a

 (Former name or former address, if changed since last report)

  

 Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 ☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)

  

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)

  

 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))

  

 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities registered pursuant to Section 12(b)
of the Act:

  

 Title of each class
  
 Trading Symbol(s)
  
 Name of each exchange on which registered

 N/A
  
 N/A
  
 N/A

  

 Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company ☒

  

 If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

  

 Resignation of Mr. Arie
Gordashnikov from his position as Chief Financial Officer

  

 On May 27, 2026, Mr. Arie
Gordashnikov resigned from his position as Chief Financial Officer of Revium Rx. (“we,” “us,” “our,”
“Revium” or the “company”) and of its subsidiaries, effective immediately. Mr. Gordashnikov’s resignation
did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

  

 Appointment of Mr. Igor
Bluvstein as Chief Financial Officer

  

 On May 27, 2026, our Board
of Directors appointed Mr. Igor Bluvstein to serve as the Chief Financial Officer of the Company and of its subsidiaries, effective immediately.

  

 Prior to his appointment as
Chief Financial Officer, from 2024 through 2025, Mr. Bluvstein served as Chief Financial Officer of Argent BioPharma Ltd. (ASX: RGT; LSE:
RGT; OTCQB: RGTLF) and from 2022 through 2024 as Chief Financial Officer of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD). Mr. Bluvstein,
44, has over seventeen (17) years of experience in financial leadership across the pharmaceutical, digital health, biotechnology, e-commerce,
and petrochemical industries. Earlier in his career, from 2020 through 2022 he served as Chief Financial & Operations Officer of MDD
Group and from 2016 through 2020 as Regional Chief Financial Officer at Frutarom Industries Ltd. (acquired by International Flavors &
Fragrances Inc. (NYSE: IFF)). Mr. Bluvstein holds a Bachelor of Arts in Accounting and Economics from the Open University of Israel. He
is a Certified Public Accountant (CPA).

  

 In connection with his appointment,
Mr. Bluvstein will receive a monthly retainer of NIS17,000 plus VAT.

   

 1

  

  

 SIGNATURE

  

 Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

  

  
 REVIUM Rx.

  
  
  

 June 1, 2026
 By:
 /s/ Amir Avraham

  
  
 Name:
 Amir Avraham

  
  
 Title:
 Chief Executive Officer

  

  

 2